Ligence Heart vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Ligence Heart

by Ligence

ElucidVivo A.3

by Elucid

AI Verdict

These tools are adjacent rather than direct competitors, as they leverage different imaging modalities for distinct diagnostic purposes within cardiology. Ligence Heart specializes in automating the analysis and reporting of 2D transthoracic echocardiography for general cardiac assessment, while ElucidVivo A.3 focuses on quantitative analysis of arterial plaque composition from CT angiography to aid in atherosclerosis patient stratification.

Choose Ligence Heart if…

Choose Ligence Heart if your primary need is to automate and enhance the efficiency of 2D transthoracic echocardiography analysis and reporting. This tool is ideal for cardiologists and sonographers seeking to improve diagnostic accuracy for conditions like heart failure and valvular diseases through automated measurements, view classification, and comprehensive report generation.

View Ligence Heart →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to optimize atherosclerosis patient stratification and treatment decisions. This system is particularly suited for cardiologists, radiologists, and vascular surgeons who need detailed visualization and measurement of plaque characteristics, including Lipid-Rich Necrotic Core, validated against histology.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Ligence Heart	ElucidVivo A.3
Pricing	Contact-for-pricing	Unknown
Deployment	Cloud-based; on-premise; hybrid	Cloud and on-premise secure deployment.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Ligence Heart

Ligence Heart is a web-based platform designed with an intuitive user interface that mimics existing programs, aiming to streamline workflow by automating measurements and reporting. This focus on automation and a familiar interface suggests a lower learning curve and higher ease of use for clinicians.

Clinical Value

ElucidVivo A.3

ElucidVivo A.3 offers novel, quantitative analysis of arterial plaque composition and stability from CT angiography, including quantification of Lipid-Rich Necrotic Core and derivation of fractional flow reserve (FFRct). Its validation against ground-truth histology provides a high level of clinical credibility and offers more profound, predictive insights for atherosclerosis patient stratification and treatment optimization.

Pricing & Value

Tie

Both tools employ a 'contact for pricing' model, which lacks transparency for direct comparison. While Tool A explicitly states HIPAA and BAA compliance, Tool B's FDA clearance and intended use in healthcare imply adherence to similar standards, making it difficult to distinguish value without specific pricing details.

Enterprise Readiness

Ligence Heart

Ligence Heart explicitly offers flexible deployment options including cloud-based, on-premise, and hybrid models, along with clear statements of BAA and HIPAA compliance. It also emphasizes integration with existing PACS, EHR, and RIS systems, demonstrating a comprehensive approach to enterprise integration and security.

Innovation

ElucidVivo A.3

ElucidVivo A.3 demonstrates greater innovation by providing a unique, histologically validated quantitative analysis of arterial plaque composition and stability from CT angiography, including FFRct. This offers new types of predictive insights for personalized atherosclerosis management, moving beyond traditional diagnostic assistance.

Support & Docs

Ligence Heart

Ligence Heart provides clear information regarding its support infrastructure, including a dedicated support email, training videos for operators, and readily available Instructions for Use (IFU) and software installation manuals in PDF format on its website. Tool B does not explicitly detail its support or documentation resources in the provided information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Ligence Heart	ElucidVivo A.3
Primary Imaging Modality	2D Transthoracic Echocardiography (TTE)	CT Angiography (CTA)
Primary Clinical Focus	Automated analysis and reporting of echocardiography for general cardiac assessment, including heart failure, cardiomyopathy, pulmonary hypertension, and valvular heart diseases.	Quantitative analysis of arterial plaque composition and stability for atherosclerosis patient stratification and treatment optimization.
Key AI Analysis Capabilities	Automated recognition of echocardiography imaging data, view classification, heart phase prediction, calculation of measurements (Area, Distance, Doppler, Volume, Strain, Spectral and Tissue Doppler), and report generation.	AI-powered quantitative analysis of arterial plaque, objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, visualizes lesion-level plaque composition, provides 3D visualization of highlighted vessels, offers rotatable curved MPR vessel views and cross-sections, and derives fractional flow reserve (FFRct).
Specialties	Cardiology	Cardiology, Radiology, Vascular Surgery
Integration with Existing Systems	PACS, EHR, RIS	PACS, EMR

Videos

Demos, reviews, and walkthroughs featuring Ligence Heart and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical application and imaging modality for each tool?

Ligence Heart automates the analysis and reporting of 2D transthoracic echocardiography to enhance diagnostic efficiency and accuracy for cardiologists and sonographers. ElucidVivo A.3 provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist physicians in atherosclerosis patient stratification and optimize treatment decisions.

What specific cardiac conditions or patient populations do these tools help diagnose or manage?

Ligence Heart aids in the recognition of diseases such as heart failure, cardiomyopathy, pulmonary hypertension, and valvular heart diseases. ElucidVivo A.3 assists in stratifying patients with atherosclerosis by offering detailed visualization and measurement of plaque characteristics.

What are the key analytical outputs and measurements provided by each tool?

Ligence Heart automates calculations for area, distance, Doppler, and volume quantification, along with automated strain, spectral, and tissue Doppler measurements. ElucidVivo A.3 objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, and derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.

How do these tools integrate with existing hospital IT infrastructure like PACS and EHR systems?

Ligence Heart is designed for integration with existing systems such as PACS, EHR, and RIS, and facilitates the transfer of echocardiography images with PHI removed. ElucidVivo A.3 is a software application that integrates with PACS/EMR, which is standard for medical imaging software.

Which medical specialties are primarily targeted by each tool?

Ligence Heart is primarily targeted towards Cardiology, specifically assisting cardiologists and sonographers with echocardiography analysis and reporting. ElucidVivo A.3 is intended for Cardiology, Radiology, and Vascular Surgery specialties due to its focus on arterial plaque analysis from CT angiography.